Europe must learn to value innovation in medicines, Bayer EU chief says

EU PERSPECTIVES - Life sciences model in Europe is a broken 'societal agreement', says Tomer Feffer of the pharmaceutical company Bayer. Companies take on long-term risk and investment with no guarantee of success — only to face delayed access, price erosion and regulatory complexity once a treatment is ready. Read more

Companies take the risk for years, but when it's time to reach patients, the system slows them down, says Tomer Feffer / Photo: Bayer